UK Markets closed
  • FTSE 100

    7,901.80
    +81.64 (+1.04%)
     
  • FTSE 250

    20,593.46
    -21.23 (-0.10%)
     
  • AIM

    889.79
    +1.03 (+0.12%)
     
  • GBP/EUR

    1.1163
    -0.0042 (-0.37%)
     
  • GBP/USD

    1.2056
    -0.0173 (-1.4106%)
     
  • BTC-GBP

    19,393.24
    -93.88 (-0.48%)
     
  • CMC Crypto 200

    535.42
    -1.43 (-0.27%)
     
  • S&P 500

    4,136.48
    -43.28 (-1.04%)
     
  • DOW

    33,926.01
    -127.93 (-0.38%)
     
  • CRUDE OIL

    73.23
    -2.65 (-3.49%)
     
  • GOLD FUTURES

    1,877.70
    -53.10 (-2.75%)
     
  • NIKKEI 225

    27,509.46
    +107.41 (+0.39%)
     
  • HANG SENG

    21,660.47
    -297.89 (-1.36%)
     
  • DAX

    15,476.43
    -32.76 (-0.21%)
     
  • CAC 40

    7,233.94
    +67.67 (+0.94%)
     

Antibody-drug Conjugates: Technology Growth Opportunities

ReportLinker
ReportLinker

Antibody-drug conjugates (ADCs) are therapies that target cancer cells with antigen-specific antibodies and highly toxic payloads. ADCs are currently generating interest among drug developers, contract manufacturing companies, regulatory agencies, and other stakeholders.

New York, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Antibody-drug Conjugates: Technology Growth Opportunities" - https://www.reportlinker.com/p06383510/?utm_source=GNW
Antibody-drug conjugates (ADCs) are therapies that target cancer cells with antigen-specific antibodies and highly toxic payloads.

ADCs are currently generating interest among drug developers, contract manufacturing companies, regulatory agencies, and other stakeholders.

The rise in the number of drug approvals has also sparked interest in further developing this technology, with several companies developing solutions for one or more ADC components.

The development of technologies is ongoing and will only increase as applications of ADCs increasingly expand into non-oncologic indications.This study covers several new technologies for the three ADC components (antibody, linker, and payload) and highlights drugs in clinical trials that display potential.

It provides an overview of key technology platforms, patents, analytical techniques, and manufacturing developments, covering the various technological advancements that may see adoption in ADC development.

It also provides an overview of the stakeholder ecosystem, identifying notable mergers, acquisitions, and partnerships.

A detailed account of the funding landscape has also been provided.

The study also analyzes the growth drivers and restraints influencing the market and identifies the key growth opportunities emerging from the changes in this space for stakeholders and market players to leverage.
Read the full report: https://www.reportlinker.com/p06383510/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001